Log in

Opko Health (NASDAQ:OPK) Upgraded at TheStreet

Last updated on Saturday, August 1, 2020 | 2020 MarketBeat

Opko Health (NASDAQ:OPK) was upgraded by analysts at TheStreet from a "d" rating to a "c-" rating in a research report issued on Thursday, TheStreetRatingsTable reports.

Several other equities research analysts also recently issued reports on OPK. Piper Sandler raised their price target on Opko Health from $6.00 to $10.00 in a research report on Friday. BidaskClub upgraded shares of Opko Health from a "buy" rating to a "strong-buy" rating in a research note on Thursday, July 23rd. ValuEngine cut shares of Opko Health from a "buy" rating to a "hold" rating in a research note on Thursday, July 2nd. Finally, Barrington Research reiterated a "buy" rating on shares of Opko Health in a research note on Friday. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of "Buy" and an average target price of $4.63.

NASDAQ OPK opened at $5.15 on Thursday. The company has a current ratio of 1.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.16. The company has a market capitalization of $3.96 billion, a PE ratio of -15.61 and a beta of 2.29. Opko Health has a 1-year low of $1.12 and a 1-year high of $6.47. The firm's fifty day simple moving average is $3.78 and its 200-day simple moving average is $2.31.

Opko Health (NASDAQ:OPK) last posted its earnings results on Thursday, July 30th. The biotechnology company reported $0.05 EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.07) by $0.12. The firm had revenue of $301.20 million for the quarter, compared to the consensus estimate of $234.57 million. Opko Health had a negative net margin of 20.69% and a negative return on equity of 7.95%. As a group, analysts predict that Opko Health will post -0.3 EPS for the current year.

In related news, CEO Phillip Md Et Al Frost acquired 400,000 shares of the business's stock in a transaction that occurred on Thursday, May 7th. The shares were acquired at an average cost of $1.95 per share, with a total value of $780,000.00. Following the transaction, the chief executive officer now owns 3,068,951 shares of the company's stock, valued at approximately $5,984,454.45. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders purchased a total of 850,000 shares of company stock worth $1,795,000 over the last ninety days. 40.90% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of OPK. HighTower Advisors LLC bought a new stake in Opko Health during the 1st quarter worth about $30,000. FARMERS & MERCHANTS TRUST Co OF LONG BEACH lifted its position in Opko Health by 108.3% during the 1st quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH now owns 25,000 shares of the biotechnology company's stock worth $34,000 after buying an additional 13,000 shares in the last quarter. United Capital Financial Advisers LLC lifted its position in Opko Health by 27.3% during the 1st quarter. United Capital Financial Advisers LLC now owns 26,101 shares of the biotechnology company's stock worth $35,000 after buying an additional 5,600 shares in the last quarter. Kovack Advisors Inc. lifted its position in Opko Health by 37.8% during the 1st quarter. Kovack Advisors Inc. now owns 29,151 shares of the biotechnology company's stock worth $39,000 after buying an additional 8,000 shares in the last quarter. Finally, Transcend Wealth Collective LLC bought a new stake in Opko Health during the 1st quarter worth about $40,000. 23.49% of the stock is currently owned by institutional investors and hedge funds.

About Opko Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services.

See Also: Trade War

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

5 Stocks That Will Benefit From the Coronavirus

Investors are digesting the damage done to their portfolios in last week’s coronavirus-induced correction. There was no place to hide from the bears who bore their claws and shredded the market from its record highs. And the reality is there is probably more volatility to come.

Many companies had reported earnings before the depth and breadth of this outbreak became apparent. And that means that it will be months before investors get a chance to see how the true impact that Covid-19 virus will have on 2020 revenue and earnings.

For risk-averse investors, it may be tempting to take a breather from the volatility. But, as the market showed yesterday, the reward is there for those willing to take the risk. Still, for the next few months – and maybe longer – this will not be like fishing in a barrel. Investors will have to take a targeted look at which companies are well-positioned in this environment.

In this special presentation, we’ll show you five companies that address one of three areas that may benefit from the coronavirus. First, there are companies whose supply chains do not involve China. In theory this means their manufacturing should be less impacted from the virus.

Second, there are companies that are in the front lines of battling the virus. This can lead you into the biotech sector. And finally, there are stocks you can look at that can benefit from consumers taking safety measures to avoid getting the virus.

View the "5 Stocks That Will Benefit From the Coronavirus".

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.